You are here

Article Text

Article menu

See original article:

Download PDFPDF

XML
Miscellaneous
Correction
  1. Antonia Johnston
  1. BMJ, London, UK
  1. Correspondence to Antonia Johnston; production.bmjopen{at}bmj.com

https://doi.org/10.1136/bmjopen-2014-006733corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Khan I, Morris S, Hackshaw A, et al. Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ Open 2015;5:e006733. doi: 10.1136/bmjopen-2014-006733

    In figure 1, the top square currently reads ‘370 Randomised’. This should read ‘670 Randomised’ as mentioned earlier in the text.

    Linked Articles